Pooja Sharma, Chief Strat/Marketing Officer, sold 4,710 shares of Procept BioRobotics Corp at $19.71 a share, worth $92.9K in total on Nov 6, 2026. Shares held after the trade: 106,471 (-4.2%).
For the quarter ended September 30, 2026, PROCEPT BioRobotics reported revenue of $98.3 million, a 18% increase compared to the same period in 2025. Despite the revenue growth, the company reported a net loss of $26.5 million for the quarter, driven by increased selling, general, and administrative expenses.
Procept BioRobotics delivered a solid Q1 2026 with 20% revenue growth, driven by record system pricing and commercial realignment, while maintaining full-year guidance despite early-quarter procedure disruption and seasonality.
PROCEPT BioRobotics reported Q3 2026 total revenue of $98.3 million, an increase of 18% year-over-year, driven by strong U.S. procedure growth and the rollout of its HYDROS systems. The company reported a net loss of $26.5 million for the quarter while reaffirming its full-year 2026 revenue guidance of $390 million to $410 million.
Term
Q3 2026
“As we enter the fourth quarter, we remain focused on executing against our full-year revenue guidance and profitability plan. Further, we remain excited to present data from WATER IV, our randomized trial comparing Aquablation to radical prostatectomy in prostate cancer, on track for the first half of 2027. We see significant opportunity and a clear path to achieving durable growth and profitability ahead.”
Larry Wood, Chief Executive Officer
“This quarter, we continued expanding our installed base and drove strong utilization in HYDROS® accounts. We delivered approximately 18% revenue growth and 22% U.S. procedure growth while accelerating our replacement cycle to transition AquaBeam systems to HYDROS.”